Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes

Inclusion Criteria: * T1D of at least 3 yrs duration. * Male or female aged 18-56 years who meets the American Diabetes Association standard T1DM criteria. * HgbA1c\<9% * Insulin requirement of \< 0.8 U/kg/d * Absence of severe hypoglycemia in the past 6 months * Absence of ketoacidosis in the past 6 months * Menstruating women must have a negative pregnancy test and be willing to avoid pregnancy during the study period. * Signed informed consent.. Exclusion Criteria: * Inability or unwillingness to give informed consent. * Prior Exenatide or Liraglutide treatment or use of any medication that could potentially affect diabetes or immunologic status * Known hypersensitivity to Exenatide or any product components * Participation in an investigational treatment trial within the last 6 weeks before enrollment. * Any medical condition that in the opinion of the investigator would interfere with safe completion of the trial such as: epilepsy, atopic disease, active Grave's disease, cystic fibrosis, sickle cell anemia, neuropathy, peripheral vascular disease, cerebrovascular disease,liver disease, HIV, or any concurrent autoimmune disease except treated and stable thyroid disease * Known severe renal impairment, end-stage renal disease or renal transplantation. * Any history of gastroparesis or other severe gastrointestinal disease, pancreatitis, thyroid nodules or malignancy with the exclusion of a history of localized basal cell carcinoma. * Uncompensated heart failure, fluid overload, myocardial infarction or liver disease within the last 6 weeks before enrollment. * Active clinically serious infections. * Positive pregnancy test in menstruating women or lactating females